Spisskomptense innen HIV/AIDS
HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x).
AIDS 2004 Sep;18(14):1875-83.
Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia.
AIDS 2005 Mar;19(6):563-7.
Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
Vaccine 2005 Jul;23(31):4011-5. Epub 2005 apr 7
Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x).
Vaccine 2006 Mar;24(10):1543-50. Epub 2005 nov 2
Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells.
AIDS 2006 Feb;20(4):627-30.
Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
AIDS 2006 Apr;20(6):813-20.
[Immunopathogenesis and therapeutic immunization in HIV-infection]
Tidsskr Nor Laegeforen 2006 Nov;126(23):3112-6.
Insulin resistance is affected by increased levels of plasma lactate but not mitochondrial alterations in skeletal muscle in NRTI-exposed HIV-infected patients.
HIV Clin Trials 2007 Sep-Oct;8(5):345-53.
PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples.
Curr HIV Res 2008 Jan;6(1):49-58.
Structured treatment interruptions enhance control of viraemia in early treated HIV-1 infection.
Sixth International Congress on drug therapy in HIV infection, 17-21 November 2003, Glasgow, Scotland (poster 26).
Cyclooxygenase-2 (COX-2) inhibitors induce T cell subset changes in patients with persistent viremia on highly active retroviral
Abstract # 514, 11th Conference on Retroviruses and Opportunistic Infections, 8-11 Feb 2004, San Fransisco, USA
Clinical Evaluation of Pain and Muscle Damage Induced by Electroporation of Skeletal Muscle in Humans.
American Society of Gene Therapy. 2-6 June 2004, Minneapolis, USA. Abstract # 157, Molecular Therapy, Vol. 9, supplement 1, May 2004.
Cellular immune responses associated with improved viral control after immunisation with a peptide-based HIV-1 immunotherapy can
Abstract # 240, AIDS Vaccine 2004 International Conference, Lausanne, Switzerland, August 30th-September 1st 2004.
Onset of HIV-1 Viremia Gives Divergent in vitro and in vivo Correlates of HIV-specific T-cell Responses.
Abstract # 474, 12th Conference on Retroviruses and Opportunistic Infections, 22-25 Feb 2005, Boston, USA.
Comparable Immunogenicity Between Patients on or off Combination Antiretroviral Therapy (CART) after Immunisation with a Novel T
Abstract #P12-03, 5th AIDS Vaccine 2006 Conference 29 Aug- 1 Sept 2006, Amsterdam.
Comparison of the decline in CD4+ T cell counts during treatment interruption in HIV-1-infected patients who did or did not rece
Abstract #MOAX0404, XVI International AIDS Conference 13-18 Aug 2006, Toronto, Canada.
IFN-g- and IL-10-producing HIV-specific T cells have suppressive properties.
Abstr. # 436, Keystone Symposium “Molecular and cellular determinants of HIV pathogenesis”, Whistler, BC, Canada, 25-30 March, 2007.
Absence of escape mutations after 15 months viraemia following efficient therapeutic immunization using conserved HIV p24-like p
Abtract #232, Keystone Symposium “HIV vaccines: From basic research to clinical trials”, Whistler, BC, Canada, 25-30 March, 2007.
Delayed-type hypersensitivity (DTH) responses may predict long-term clinical benefit of peptide-based therapeutic immunization.
1st International Symposium on Genetic and Immune Correlates of HIV Infection and Vaccine-Induced Immunity, Budapest, Hungary, 10-13 of June, 2007.
Differential mitochondrial DNA loss in T cell subsets of HIV-infected treatment-naive and NRTI-exposed patients.
11th European AIDS Conference / EACS, 24-27 October 2007, Madrid, Spain, Abstract 9.5/0.1.
“Peptide-based therapeutic immunisations targeting dendritic cells in chronic HIV
- juni 2006
- Dag Kvale